Tag: sage therapeutics

December 23, 2019

Pharma Trends 2019: FDA Approvals Make Waves Through Market

INN takes a look at the pharma trends of 2019 that have shaken up the space this year and created...
March 20, 2019

Sage Therapeutics Wins First Postpartum Depression Drug Approval

The US Food and Drug Administration regards Sage Therapeutics' drug Zulresso as a breakthrough therapy to treat postpartum depression.
November 6, 2018

Sage Therapeutics Announces Third Quarter 2018 Financial Results

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported...
June 12, 2018

Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meetin

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced...
April 30, 2018

Key Stock Catalysts in the FDA Drug Application Process

Pharmaceutical and biotech companies in the US must follow a standard process to advance a new drug candidate through nonclinical...
September 27, 2016

Sage Therapeutics Announces Product Pipeline Review

Global Markets Direct's, 'Sage Therapeutics Product Pipeline Review - 2016', provides an overview of the Sage Therapeutics, Inc.'s pharmaceutical research...